1. Pink Sheet
  2. >>Compliance
  3. >>Marketing & Advertising

FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations

 
• By Michael Cipriano

HHS blog post details activity of US FDA's Office of Prescription Drug Promotion during a year in which the office has only issued one enforcement letter, continuing a downward trend.

Puzzle

The Department of Health and Human Services (HHS) is spotlighting the oversight of prescription drug advertising in a year when the US FDA's Office of Prescription Drug Promotion (OPDP) could set a record low for enforcement letters issued.

A May 30 HHS blog post features a video with Mike Sauers, a staff supervisor for OPDP's advertising...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Marketing & Advertising

More from Compliance

Titanium Dioxide Stays: EU Decides Not To Pull Plug On Widely Used Excipient

 
• By Neena Brizmohun

While titanium dioxide is banned as a food additive in the EU, the European Medicines Agency has convinced the European Commission to allow its continued use in the many thousands of medicines in which it is currently used.

UK Medicines Shortages Inquiry Eyes Full Reshoring of Drug Manufacturing

 
• By Neena Brizmohun

A newly launched UK government inquiry is seeking to learn how viable it would be to bring back domestic control over the entire drug manufacturing pipeline.

Big PBM Dominance Enabled By Affiliated Third Party Administrators Limiting Choices, FTC Told

 
• By Cathy Kelly

Complaints about TPAs offer an explanation of why self-funded employers continue to use the big three PBMs despite concerns about those relationships. Proposed solutions include banning retaliatory fees and data withholding.